Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05775887 Completed - COVID-19 Clinical Trials

A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.

Start date: May 8, 2023
Phase: Phase 1
Study type: Interventional

This will be a single centre, Phase 1, First-In-Human , Randomized, Active-controlled (2- arm) Double-blind, single dose, parallel design study. The study will be conducted in a young healthy adult population aged ≥ 18 - ≤ 50 years. This study will consist of a single cohort of 70 subjects (35 receiving a single dose of UQSC2 vaccine and 35 subjects receiving a single dose of a TGA (Therapeutic Goods Administration) registered SARS-CoV-2 vaccine NVX-CoV2373).

NCT ID: NCT05774418 Completed - COVID-19 Clinical Trials

Evaluation of the Impact of the Anti COVID-19 Vaccination Campaign Addressed to the Employees of an Italian Hospital.

Start date: December 28, 2020
Phase:
Study type: Observational

Health workers, especially those in patient-facing roles, had a significantly increased risk of COVID-19 infection, having serious outcomes, and risking spreading the virus to patients and staff. Vaccination campaign planning suggests allocating initial supplies of BNT162b2 vaccine to health workers given the importance of early protection to safeguard the continuity of care to patients. The aim of the study is to assess the effectiveness and safety of BNT162b2 vaccine among the health workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS (FPG). The retrospective cohort study will be conducted among health staff working at the FPG. Vaccination data will collect from hospital records. The primary end points will be vaccine effectiveness and safety.

NCT ID: NCT05774405 Completed - COVID-19 Clinical Trials

Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients

Start date: July 1, 2020
Phase: Phase 2
Study type: Interventional

The goal of this randomized placebo-controlled study is to investigate the short-term effects of transdermal estrogen therapy on postmenopausal women with COVID-19 disease. The main question[s] it aims to answer are: - the clinical outcomes with adding estrogen treatment to conventional therapy of Covid-19 disease - the biochemical outcomes with adding estrogen treatment to conventional therapy of Covid-19 disease All participants received favipiravir for a week according to the national guidelines published by the Health Ministry of Turkish Republic at that time. As an intervention, transdermal estradiol patch (7.8 mg patch/week) was applied for 14 days on the upper buttock of the patients in experimental arm. As a placebo, hydrogel patch (adhesive hydrogel patch/week) was applied to the female patients for 14 days. Researchers compared experimental and control groups to see if the impact of adding estrogen on the clinical course of Covid-19 disease

NCT ID: NCT05771857 Completed - Obesity Clinical Trials

Obesity: an Underappreciate Risk Factor for Severe Form of COVID-19

Start date: March 1, 2020
Phase:
Study type: Observational [Patient Registry]

Our study has the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19.

NCT ID: NCT05771727 Completed - Clinical trials for Neuromuscular Diseases

Impact of Covid-19 Pandemic on Children With Neuromuscular Disease and Their Parents in Turkey: Parent Perspective

Start date: July 1, 2021
Phase:
Study type: Observational

Parents of children with neuromuscular disease have been already at risk of depression, anxiety and burden. Additionally, the daily lives of children with neuromuscular disease and their parents have been significantly affected by the COVID-19 pandemic. Therefore, this study investigated parents' perspective on the effect of the COVID-19 pandemic on children with neuromuscular diseases and themselves.

NCT ID: NCT05770466 Completed - COVID-19 Clinical Trials

Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.

Start date: April 1, 2022
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy of subcutaneous ropeginterferon alfa 2b ( P1101combined with standard of care (SOC) compared with standard care alone in hospitalized adults with moderate COVID 19.

NCT ID: NCT05770336 Completed - COVID-19 Pneumonia Clinical Trials

STUDIO DELLE MANIFESTAZIONI CARDIOVASCOLARI A LUNGO TERMINE MEDIANTE TECNICHE DI IMAGING

LONG-COVID
Start date: March 9, 2022
Phase:
Study type: Observational

The aim of the project is to identify the prevalence and characteristics of long-term cardiovascular changes in Covid-19 infection.

NCT ID: NCT05770193 Completed - Clinical trials for Post COVID-19 Condition

Effect of Kinesio Tape Versus Diaphragmatic Breathing Exercise In Post COVID-19

Start date: March 11, 2023
Phase: N/A
Study type: Interventional

According to WHO, current evidence suggests some people experience a variety of long-term effects after they recover from their initial illness. These effects are collectively known as post COVID-19 condition or "long COVID. While most people who develop COVID-19 fully recover, some people develop effects like fatigue, breathlessness, functional activities and cognitive dysfunction. At present, there is no specific medication therapy for people with post COVID-19 condition.

NCT ID: NCT05766176 Completed - COVID-19 Clinical Trials

Study of the Effectiveness of The COVID-19 Vaccine

Start date: July 1, 2022
Phase:
Study type: Observational

This descriptive study examines neutralizing antibody levels against COVID-19 in health workers before and after the 2nd booster of the COVID-19 vaccine in Surakarta, Indonesia.

NCT ID: NCT05766111 Completed - COVID-19 Clinical Trials

COVID-19 Seroprevalence Among Healthcare Workers of a Large COVID-19 Hospital in Rome

Start date: June 1, 2020
Phase:
Study type: Observational [Patient Registry]

Healthcare workers are at the forefront against COVID-19, worldwide. Since Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS was enlisted as a COVID-19 hospital, the healthcare workers deployed to COVID-19 wards were separated from those with limited/no exposure, whereas the administrative staff were designated to work from home. Between June and July 2020, an investigation will conduct to evaluate the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin (IgG) antibodies among the employees of the FPG using point-of-care (POC) and venous blood tests. Sensitivity, specificity, and predictive values were determined with reverse-transcription polymerase chain reaction on nasal/oropharyngeal swabs as the diagnostic gold standard.